NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions

#NRXS NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/NRXS/neur-axis-repo...

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives NeurAxis (NYSE American: NRXS) announced new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (PENFS), adding approximately 45 million covered lives and bringing PENFS total national coverage to roughly 100 million covered lives.The company’s FDA-cleared IB-Stim is approved for patients 8 years and older with functional abdominal pain related to IBS and functional dyspepsia. NeurAxis noted a Category I CPT code effective January 1, 2026, incorporation of PENFS into national clinical guidelines, and a strengthened balance sheet as positioning factors for expected revenue growth and margin expansion.

#NRXS NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

www.stocktitan.net/news/NRXS/neur-axis-achi...

NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain NeurAxis (NYSE American: NRXS) was awarded a Veterans Affairs Federal Supply Schedule contract effective December 1, 2025, listing its IB-Stim device as the first product on the FSS.The award creates a federal commercial pathway into the VA health system, which serves nearly 7 million active patients annually. IB-Stim is an FDA-cleared percutaneous electrical nerve field stimulator for functional abdominal pain, approved for patients age 8 and older and described as the only FDA-cleared therapy for functional dyspepsia (FD). The company cited a Category I CPT code effective January 1, 2026 and said it will dedicate sales resources to VA channels to support commercialization into 2026.

#NRXS NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain

www.stocktitan.net/news/NRXS/neur-axis-secu...

NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating

#NRXS NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

www.stocktitan.net/news/NRXS/neur-axis-repo...

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population NeurAxis (NYSE:NRXS) received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) device to treat functional abdominal pain associated with functional dyspepsia (FD) and FD-related nausea in patients aged 8 years and older on October 24, 2025. The FDA reviewed randomized trials and real-world evidence, extrapolating pediatric data to adults. This is described as the first FDA clearance for a treatment addressing adult functional dyspepsia. NeurAxis noted the new indication will use the Category I CPT code effective January 1, 2026 to report PENFS procedures.

#NRXS NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

www.stocktitan.net/news/NRXS/neur-axis-awar...

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues NeurAxis (NYSE American: NRXS) reported strong Q2 2025 financial results, with revenues increasing 46% year-over-year to $894,000. The medical technology company, focused on neuromodulation therapies, achieved significant milestones including FDA clearance for expanded pediatric treatment and secured key academic society guidelines recommendation for their PENFS technology.Operating expenses decreased 10% year-over-year, while operating loss improved by 22%. The company maintained a cash balance of $6 million, bolstered by a $5 million equity financing round. NeurAxis expanded its covered lives to 53 million and received a new Category I CPT code for PENFS procedures, effective January 2026. The company expects to achieve breakeven in 2026.

#NRXS NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

www.stocktitan.net/news/NRXS/neur-axis-repo...

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives NeurAxis (NYSE: NRXS) has secured medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology from two health insurers, adding 700,000 covered lives in Connecticut and Massachusetts. This brings their total national coverage to approximately 53 million members. The company's FDA-cleared IB-Stim device treats functional abdominal pain associated with IBS and Pediatric Functional Dyspepsia in patients aged 8-21 years through non-surgical electrical stimulation of cranial nerves. The technology has been included in pediatric academic society's treatment guidelines, and a Category I CPT code will become effective January 1, 2026, which is expected to improve reimbursement and adoption across children's hospitals.

#NRXS NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

www.stocktitan.net/news/NRXS/neur-axis-anno...

Major Medical Guidelines Back NeurAxis $3B IBS Treatment for Children, Only FDA-Cleared Option Leading pediatric societies endorse NeurAxis's PENFS technology for IBS pain. Exclusive FDA-cleared treatment targets $3B market. See coverage implications.

#NRXS NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS

www.stocktitan.net/news/NRXS/neur-axis-achi...

Medical Tech Pioneer NeurAxis Raises $5M to Accelerate Breakthrough Neuromodulation Treatments $5M financing at $3.25/share backs expansion of innovative neuromodulation therapies for chronic conditions. Craig-Hallum leads institutional round. See full terms.

#NRXS NeurAxis Announces $5.0 Million Registered Direct Offering

www.stocktitan.net/news/NRXS/neur-axis-anno...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue May 20th - #WULF #NRXS #RIG #TDOC #SYTA #QUBT #QMCO #NVAX #MGNX #LEU #KULR #IQ #HUT #FTRE #ESPR #DAWN #CGC #CERS #ATER #ASST - More: crystalequityresearch.com/SmCpStr/ - #smallcap

NeurAxis Gains FDA Clearance for Pediatric Treatment, Doubling Addressable Market NeurAxis Inc. (NRXS) has secured a major regulatory milestone, receiving FDA 510(k) clearance for its IB-Stim™ device to treat Functional Dyspepsia (FD) and a

Big win for #NeurAxisInc! ( #NRXS)
FDA clears IB-Stim for pediatric IBS treatment, doubling their market to 16M patients. Transforming lives with innovative neuromodulation!
#Healthcare #MedTech #NRXS #neuromodulation
prismmarketview.com/neuraxis-gai...

News; ( NYSE: #NRXS ) 5 Hot Stocks to Consider Trading Today- NRXS, SYTA, QBTS, EDBL, and EYEN

BREAKING NEWS: ( NYSE: #NRXS ) NeurAxis Receives Historic FDA Clearance for IB-Stim to Treat Pediatric Functional Dyspepsia and Associated Nausea

Breakthrough: First-Ever FDA Clearance for Pediatric Functional Dyspepsia Treatment Doubles Market Potential Revolutionary non-invasive treatment targets ages 8-21, addressing previously untreatable functional dyspepsia. New clearance expands addressable market. See clinical impact.

#NRXS NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

www.stocktitan.net/news/NRXS/neur-axis-awar...

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues NeurAxis (NYSE: NRXS) reported strong Q1 2025 financial results with revenues increasing 39% year-over-year to $896,000. The company achieved significant operational milestones, including expanding covered lives to 51 million from 4 million in December 2023. Key developments include receiving a new CPT Category I code for PENFS procedures (effective January 2026), FDA clearance for expanded IB-Stim label (ages 8-21), and 510(k) clearance for their rectal expulsion device (RED). The company's operating loss improved by 9% YoY (excluding one-time legal settlement), though gross margin declined to 84.4% from 88.4%. With $2.0 million cash on hand and no long-term debt, NeurAxis is treating 300 patients quarterly through PO/PAP programs, representing just 0.2% of their 600,000 potential patient market.

#NRXS NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

www.stocktitan.net/news/NRXS/neur-axis-repo...

NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues NeurAxis (NYSE: NRXS) reported strong Q4 2024 financial results with revenues increasing 43% to $761,000 compared to Q4 2023. The company's operating loss improved by 10% year-over-year.Key operational highlights include expanding covered lives to 51 million from 4 million in 2023, receiving a new CPT Category I code for PENFS procedures effective January 2026, and FDA clearance for expanded IB-Stim label (ages 8-21) and the rectal expulsion device (RED).Financial metrics for FY2024 show:Annual revenue of $2.7 million, up 9% from 2023Gross margin of 86.5%Operating loss of $7.2 millionCash balance of $3.7 million as of December 31, 2024The company treated over 1,000 pediatric patients in the past 12 months, representing 0.1% of the 600,000 children suffering from IBS in the U.S.

#NRXS NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

www.stocktitan.net/news/NRXS/neur-axis-repo...

NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device NeurAxis's IB-Stim device for adolescent IBS pain secures major insurance coverage, expanding from 4M to 51M covered lives. FDA-cleared device offers drug-free treatment option.

#NRXS UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States

www.stocktitan.net/news/NRXS/update-neur-ax...

NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal NeurAxis secures Molina Healthcare coverage for IB-Stim, its non-surgical IBS pain treatment device, expanding access to 5.1M more patients across 13 states. Total coverage now reaches 51M lives.

#NRXS NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

www.stocktitan.net/news/NRXS/neur-axis-anno...

NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range NeurAxis reports breakthrough year for IB-Stim pediatric IBS treatment, expanding insurance coverage 12-fold and receiving FDA approval for broader age range. RED device launch set for Q1 2025.

#NRXS NeurAxis Inc. Issues Letter to Shareholders

www.stocktitan.net/news/NRXS/neur-axis-inc-...

NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives NeurAxis reports strong Q4 growth with $800K revenue, expands IB-Stim age range to 8-21 years, and achieves major insurance coverage milestone amid commercialization plans.

#NRXS NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

www.stocktitan.net/news/NRXS/neur-axis-inc-...

NeurAxis Secures FDA Clearance for Revolutionary Chronic Constipation Testing Device NeurAxis's innovative RED device receives FDA 510(k) clearance, targeting a $1.5B chronic constipation testing market. Launch planned for early 2025 with Medicare coverage.

#NRXS NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

#news #StockMarket #investing

www.stocktitan.net/news/NRXS/neur-axis-inc-...

NEWS: ( NYSE: #NRXS ) NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

#StockMarket #News